Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement  by Lip, Gregory Y.H. et al.
5t
f
i
1398 Correspondence JACC Vol. 58, No. 13, 2011
September 20, 2011:1396–92. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of
omeprazole and pantoprazole on the pharmacodynamics and pharma-
cokinetics of clopidogrel in healthy subjects: randomized, placebo-
controlled, crossover comparison studies. Clin Pharmacol Ther 2011;
89:65–74.
3. Ferreiro JL, Angiolillo DJ. Antiplatelet therapy: clopidogrel plus
PPIs—a dangerous combination? Nat Rev Cardiol 2009;6:392–4.4. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA
2010 expert consensus document on the concomitant use of proton
Improvement and Integrated Discrimin
P
u
c
n
B
r
d
R
HAS-BLED score  Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisp
mprovement; NRI  net reclassification improvement.pump inhibitors and thienopyridines: a focused update of the
ACCF/ACG/AHA 2008 expert consensus document on reducing the
gastrointestinal risks of antiplatelet therapy and NSAID use: a report of
the American College of Cardiology Foundation Task Force on Expert
Consensus Documents. J Am Coll Cardiol 2010;56:2051–66.
. Bonello L, Tantry US, Marcucci R, et al., Working Group on High
On-Treatment Platelet Reactivity. Consensus and future directions on
the definition of high on-treatment platelet reactivity to adenosine
diphosphate. J Am Coll Cardiol 2010;56:919–33.CORRESPONDENCE
Research Correspondence
Comparative Analysis of the
HAS-BLED Score With Other Bleeding Risk Scores,
Using Estimates of Net Reclassificationation ImprovementTo the Editor: We thank Drs. Rosenstein and DiMaggio for their
comments. We agree that estimates of net reclassification
improvement (NRI) and integrated discrimination improve-
ment (IDI) offer potentially useful analytic methods offering
incremental information relative to the c-statistic. Based on
their suggestions, we have calculated these statistics to comple-
ment the results provided in Table 7 of our paper (1), based on
he low-, moderate-, and high-risk categorizations resulting
rom the different bleeding risk schema. Table 1 summarizes the
results in terms of NRI and IDI, which together with our other
analyses presented in the original paper, would reinforce the
incremental utility of the HAS-BLED index over these other
schemas, with the exception of the score by Shireman et al. (2),
which is based on the NRI. As emphasized, the HAS-BLED
score also has the advantage of simplicity. We concur with Drs.
Rosenstein and DiMaggio that the NRI and IDI methodology
should be considered in the assessment of future contributions
as we seek to optimize the predictive accuracy of bleeding risk
prediction for patients with atrial fibrillation undergoing anti-
coagulation.
We also agree that bleeding risk with the new oral antico-
agulant agents may be different from warfarin, and our original
paper presents the risk factors for bleeding in warfarin-only
patients (Table 6 [1]) and the comparison against other scores
in warfarin-only patients (and not in combination with ximela-
gatran users, as implied in their letter).
As Drs. Rosenstein and DiMaggio suggest, further analyses
of the HAS-BLED scores in “real-world” nontrial populations
Statistical Comparison of the NRI and IDI Between HAS-BLED and Other ConTable 1 Statistical Comparison of the NRI and IDI Between HAS-BLED a
Difference in Predicted Probability of an Event
HAS-BLED Versus Patients With Event Patients Without Event
Shireman et al. (2) 0.644 0.025 0
HEMORR2HAGES (3) 0.400 0.015 0
Beyth et al. (4) 0.797 0.031 0
Kuijer et al. (5) 0.850 0.033 0would reinforce the usefulness of this score in the nontrial
cohorts, and our ongoing analyses in such ‘real world’ cohorts
again confirm the consistency of the usefulness of this score in
assessing bleeding risk in patients with atrial fibrillation (6).
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We read with interest the paper by Lip et al. (1) describing the
comparative validation of the HAS-BLED (Hypertension, Ab-
normal Renal/Liver Function, Stroke, Bleeding History or Predis-
position, Labile INR, Elderly, Drugs/Alcohol Concomitantly)
score. There are difficulties in evaluating the usefulness of new risk
models, and a simple increase of the c-statistic does not necessarily
reflect a clinically relevant improvement in describing a patient’s
risk status. Newer modeling has suggested that the net reclassifi-
cation improvement (NRI) and integrated discrimination im-
provement (IDI) be evaluated in the assessment of the usefulness
of potential biomarker(s) within an established risk-stratifying tool
(2). When comparing models, using the NRI may reveal the
advantages obtained by reclassifying a patient from one risk
category to another. Although the model in the HAS-BLED
comparative analysis seemed to be properly calibrated with the
Hosmer-Lemeshow test, the actual number of patients who were
reclassified into a different risk category (which subsequently
resulted in a change of therapy) is not specified. Therefore, the
number of reclassified patients who either were spared or experi-
enced a bleeding event was not reported. Thus, without the NRI,
it remains questionable if the reclassification yielded an improve-
ment by using the HAS-BLED model over the other schemas. If
an increase of the c-statistic does not yield a meaningful change in
a patient’s therapeutic strategy, then the utility of such testing is
not apparent. Proclaiming that the HAS-BLED score offers useful
predictive capacity for bleeding risk should not be based solely on
the area under the curve but should also include integrated
sensitivity and specificity, both components of the IDI, as well as
improvements in the reclassification tables. Therefore, although we
agree with the authors that the HAS-BLED score may provide a
valuable tool in discriminating patients based on bleeding risk,
these additional measures will offer an incremental improvement
over the c-statistic, and validate the usefulness of this score.
In addition, this combined analysis included patients treated
with ximelagatran, a direct thrombin inhibitor found to have
adverse effects on liver function testing (3). We suggest that themight be different and also may vary according to specific anatomic
sites. For example, dabigatran was associated with less intracranial
hemorrhage yet a greater risk of gastrointestinal bleeding com-
pared with warfarin in the RE-LY (Randomized Evaluation of
Long Term Anticoagulant Therapy With Dabigatran Etexilate)
study (4). This variability has implications for any future risk
model and suggests that each agent may require independent
validation in separate cohorts.
Finally, the limitation of analysis of all major bleeding in this
study to the on-treatment analysis may be less reflective of the
world outside of the clinical trial than a protocol that strictly
adheres to intention-to-treat analysis (5).
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